Gainers

• Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session.
• ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their outstanding shares is at $6.4 million.
• SL Science Holding (NASDAQ:SLBT) stock rose 10.74% to $0.8. The company's market cap stands at $405.0 million.
• Can Fite Biopharma (AMEX:CANF) stock increased by 10.32% to $1.71. The company's market cap stands at $3.3 million.
• Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 10.0% to $0.4. The company's market cap stands at $3.2 million.
• Streamex (NASDAQ:STEX) stock rose 8.98% to $0.36. The company's market cap stands at $38.3 million. As per the news, the Q3 earnings report came out today.

Losers

• Basel Medical Group (NASDAQ:BMGL) shares fell 24.0% to $0.52 during Thursday's pre-market session. The market value of their outstanding shares is at $9.2 million.
• Beyond Air (NASDAQ:XAIR) shares declined by 23.96% to $2.0. The company's market cap stands at $2.5 million. As per the news, the Q2 earnings report came out yesterday.
• OptimizeRx (NASDAQ:OPRX) shares decreased by 20.9% to $7.08. The company's market cap stands at $165.5 million. As per the news, the Q3 earnings report came out yesterday.
• Xenetic Biosciences (NASDAQ:XBIO) shares declined by 16.41% to $1.56. The company's market cap stands at $4.3 million.
• Co-Diagnostics (NASDAQ:CODX) stock decreased by 12.32% to $0.24. The market value of their outstanding shares is at $2.4 million. As per the press release, Q3 earnings came out 2 days ago.
• Bone Biologics (NASDAQ:BBLG) stock fell 9.86% to $0.32. The company's market cap stands at $1.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.